The aim of the research. An intensive research is underway to create new methods for the synthesis of fl uorine-18 labeled radiopharmaceuticals. Th e aim of this work is to select iodoaliphatic carboxylic acids and esters for radiopharmaceuticals labeling. Material and methods. A simple way to obtain z-yodalifi c carbonic acids and complex esters from commercially available cyclic ketones has been developed. Automatic synthesis of 18F-fl uoroproprostatic groups and 18F fl uoride peptide agents is successfully carried out using new original materials and various purifi cation methods with solid phase cartridges Results. In further work, it is planned to use diff erent 18F-fl uoroproproprostatic groups for synthesis with various peptide agents. Conclusion. Based on these compounds 18F-fl uoroproproprostatic groups were synthesized. Octreotid as an analogue of somatostatin, the non-immunoglobulin-specifi c frame proteins (designed ankyrin repeat proteins) for targeted imaging of tumor cells hyperexpressing Her-2/neu, and prostate-specifi c membrane antigen (PSMA) inhibitor are signifi cant peptide agents.

The paper describes a new radiopharmaceutical for diagnosis of lung cancer obtained on the basis of a radiolabeled 11C oligonucleotide and the study of its effectiveness in-vivo. As a result of the synthesis, an aptamer to lung cancer containing 11С in the 3'-position was obtained and remained stable for 60 minutes. Prior to xenotransplantation of human lung cancer cells, the mice were immunosuppressed. Tumour volumes and locations were monitored using PET/CT. The study of accumulation of the radiopharmaceutical in the organs of mice in vivo has shown that the 11C-labeled lung cancer aptamer specifically binds to lung cancer cells. A radiopharmaceutical based on 11C-labeled LC aptamer against lung cancer is a promising drug for lung cancer diagnosing